Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.
The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...
Analysts are out in force on Netflix, with shares sliding after the streaming service posted its slowest revenue growth rate ...
GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ...
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential. Bepirovirsen is specifically approved for patients ...
Catalysts spur chemical reactions used across industries, from producing fuels and medicines to manufacturing chemicals and ...
If anything, it might be slightly worse than expected. Leading the inflationary economic data-pack, the U.S. Bureau of Labor ...
More than 275 new complaints have been filed over Millie Moon diapers in the past month, with parents describing burns and ...
UNLOXCYT receives NCCN Category 2A Preferred Designation for laCSCC patients ineligible for surgery or radiation. The ...
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...
How good-looking do you think you are? In two studies, optimistic, emotionally stable, and college-educated adults tended to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results